MBM ScienceBridge GmbH, Georg-August-University Göttingen, University Medical Center and MRC Technology a UK medical research charity, are collaborating on new therapy for neurodegenerative diseases.
MBM ScienceBridge GmbH, Georg-August-University Göttingen, University Medical Center and MRC Technology, a UK medical research charity, have signed an exclusive license agreements for the development of a novel therapy of neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x. The aim is to develop a therapy for Alzheimer's Disease (AD).
The licence negotiated by MBM ScienceBridge GmbH, the technology transfer organization of the Georg-August-Universität Göttingen, will enable UMG to access the world-class antibody humanization expertise of MRCT’s Centre for Therapeutics Discovery and the work of its Therapeutic Antibody Group, led by Dr David Matthews and gives MRCT the opportunity to use its renowned capability to take lab tool compounds and turn them into clinical candidates, which will then be licensed to the pharmaceutical and biotech industry.
MRCT receives an exclusive worldwide license to the IP rights of UMG related to a novel therapeutic approach for the treatment of sporadic and familial AD, based on a panel of unique antibodies developed by its scientist Prof. Dr. Thomas Bayer. MRCT and UMG will then receive downstream payments dependent on the successful development and out-licensing of the antibody. This income will be used for further research within the organisations.
Notes to Editors
MBM ScienceBridge GmbH
E-mail: firstname.lastname@example.org, Phone: +49-551-30724150
Liezel Tipper PR & Communications Manager, MRC Technology
E-mail: email@example.com, Phone: +44(0) 20 7391 2772
About Alzheimer's Disease
The occurence of Alzheimer's Disease is estimated at 5% of people between 65 to 75 years of age, and at 24% of persons over the age of 85 years. It is the most frequendt type of dementia in elderly people. The prevalence of alzheimer's Disease is estimated at 2.2% among the populations of the seven major markets of USA, Japan, UK, Germany, France, Italy & Spain. The increasing aging population particularly in countries like China or Brazil, will dramatically increase the total number of patients. The lack of efficacious drugs implies high growth potential, shaping a competitive and dynamic therapeutic area. Revenues forecast these markets are of several US$ billions a year, having experienced formidable growth.
About MBM ScienceBridge GmbH
The MBM ScienceBridge GmbH is a fully owned subsidiary of the University of Göttingen and acts on its behalf as a technology transfer interface to companies around the world. The IP portfolio managed by MBM ScienceBridge covers innovation in the areas of Life Sciences, Chemistry, Physics, Optics, Agriculture, Forestry and Medical Technologies.
Contact: www.sciencebridge.de, firstname.lastname@example.org, +49-551-30724151.
About Georg-August-University Göttingen
The Georg-August-Universität Göttingen, Universitätsmedizin, Germany, was founded in 1737 in the spirit of the Enlightenment, which laid and continues to laythe foundation - both in the natural sciences and in the humanities - for the present day University's excellent reputation.
About MRC Technology
MRCT (www.mrctechnology.org) is an independent life science medical research charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application. Four of MRC Technology’s projects have led to approved drugs (Tysabri®, Actemra®, Entyvio®, Keytruda®) and the company has a strong pipeline in development.
Stefan Weller | idw - Informationsdienst Wissenschaft
North and South Cooperation to Combat Tuberculosis
22.03.2018 | Universität Zürich
Researchers Discover New Anti-Cancer Protein
22.03.2018 | Universität Basel
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
22.03.2018 | Trade Fair News
22.03.2018 | Earth Sciences
22.03.2018 | Earth Sciences